

Strategic Report, Report of the Directors and

Financial Statements

for the Year Ended 31st March 2021

for

Dr Reddy's Laboratories (UK) Limited

Contents of the Financial Statements
for the year ended 31st March 2021

	Page
Company Information	1
Strategic Report	2
Report of the Directors	6
Report of the Independent Auditors	8
Income Statement	12
Other Comprehensive Income	13
Balance Sheet	14
Statement of Changes in Equity	15
Notes to the Financial Statements	16

Dr Reddy's Laboratories (UK) Limited

Company Information
for the year ended 31st March 2021

DIRECTORS:	K S Reddy V N Mannam S McAuliffe P Aghanian
SECRETARY:	R Sane
REGISTERED OFFICE:	6 Riverview Road Beverley East Yorkshire HU17 0LD
REGISTERED NUMBER:	01729064 (England and Wales)
AUDITORS:	cbaSadofskys Statutory Auditors Princes House Wright Street Hull East Yorkshire HU2 8HX
BANKERS:	Bank of Scotland Aldgate House 1/4 Market Place Hull HU1 1RA
SOLICITORS:	Taylor Vinters Merlin Place Milton Road Cambridge CB4 0DP

Strategic Report
for the year ended 31st March 2021

The directors present their strategic report for the year ended 31st March 2021.

REVIEW OF BUSINESS

The key financial highlights are as follows:

	£	£	£	£	2021	2020	2019	2018
Turnover - UK, Europe and other countries					38,892,768	36,748,791	26,658,783	40,429,896
Turnover growth - United Kingdom					5.8%	37.8%	-34.1%	7.3%
Profit before tax					3,060,487	4,260,772	2,552,760	7,941,065
Profit before tax margin					7.9%	11.6%	9.6%	19.6%

The company continues to grow year on year in terms of turnover. After previous strong years in our branded products this year saw a sharp decline in this area due to much lower cost generics. However, this was more than supplemented in excellent sales through the hospital channel with both tender wins and off contract sales contributing.

In the retail channel we continue to grow and develop our relationships with key customers. We have increased our range sell at increased but responsible prices. Our stronger supply chain has also allowed us to be less boom and bust on products and maintain to forecast in certain areas.

PRINCIPAL RISKS AND UNCERTAINTIES

The company has identified the principal areas of risk that it faces as:

Financial instrument risk

The company has established a risk and financial management framework whose primary objectives are to protect the company from events that hinder the company's performance objectives. The objectives aim to ensure sufficient working capital exists and monitor the management of risk at a business unit level.

Impact of pharmaceutical regulations

The business is subject to various regulations and any tightening of these could have a negative impact on earnings.

Price risk

The company sells generic pharmaceutical products. The prices of such products tend to reduce on account of severe pricing pressure and competition. This risk is managed by maintaining adequate levels of stock and introducing new products on expiry of patents.

Foreign exchange risk

The company sells and purchases some products in foreign currencies. The risk is mitigated by monitoring foreign exchange rates on a daily basis and taking foreign exchange cover, if required.

Credit risk

Credit checks are carried out on all customers. Amounts outstanding for both time and credit limits are regularly monitored. The company has little experience of material bad debts in general.

Liquidity risk

Liquidity is the risk that the company will encounter difficulty in meeting obligations associated with financial liabilities. The company manages its cash flow to ensure that sufficient liquid resources are available to meet its operating needs.

Interest rate and cash flow risk

The company had a favourable cash balance during the year and therefore does not consider that interest rates or cash flow pose a significant risk.

Strategic Report
for the year ended 31st March 2021

SECTION 172(1) STATEMENT

The Board of Directors, in line with their duties under s172 of the Companies Act 2006, act in a way they consider, in good faith, would be most likely to promote the success of the Company for the benefit of its members as a whole, and in doing so have regard to a range of matters when making decisions for the long term. Key decisions and matters that are of strategic importance to the Company are appropriately informed by s172 factors.

At Dr. Reddy's, our Board of Directors, management and employees are committed to upholding high standards of corporate governance and business ethics. We firmly believe that timely disclosures, transparent accounting policies, rigorous internal control systems and a strong and independent Board go a long way in preserving shareholder trust while maximising long-term shareholder value.

This s172 statement explains how the Dr. Reddys Directors:

- Have engaged with employees, suppliers, customers and others; and
- Have had regards to employee interests, the need to foster the company's business relationships with suppliers, customers and others, and the effect of that regards, including on the principal decisions taken by the company during the financial year.

The s172 statement focuses on matters of strategic importance to Dr. Reddys, and the level of information disclosed is consistent with the size and the complexity of the business.

General confirmation of Directors' duties

Dr. Reddys have a number of Committees appointed by the Board at group level to focus on specific areas and take informed decisions within the framework of delegated authority, and make specific recommendations to the Board. All decisions and recommendations of the committees are placed before the Board for information or for approval.

When making decisions, each Director ensures that they act in the way they consider, in good faith, would most likely promote the Company's success for the benefit of its members as a whole, and in doing so have regard (among matters) to:

The likely consequences of any decision in the long term

The Directors understand the business and the demand to innovate the latest products in order to find the most effective treatments in the pharmaceutical market. Dr. Reddy's vision and goal of 'Good Health Can't Wait' is what the business drives and strives for. The strategy set by the Board as a leader in the pharmaceutical industry is to ensure good health can be delivered to those who need it, and to promote wellness among them.

Whilst investing for the future, the Board also recognises that we must focus on meeting the current supply and demand of pharmaceuticals.

The Directors are guided by our principles - Empathy and Dynamism - which provide both guidance for our current behaviour and inspiration for our future actions.

The interests of the company's employees

At Dr. Reddy's employees are at the heart of our business. The Management team invites a fair and open two way relationship with all employees. We believe in respecting every individual, regardless of position. At Dr Reddy's employees are heard and have the opportunity to express their opinion. Organisation believes in equality and discourage any discrimination based on any caste, creed, race, religion age and gender etc. We are committed to employee's safety and well-being. Our HR policies are well documented and available to each employee. Management assumes responsibility that such policies are adhered to.

The talented and capable people have played a major role in powering and defining the growth of Dr. Reddys. We believe that when people with diverse skills are bound together by a common purpose and value system, they can make magic.

The need to foster the company's business relationships with suppliers, customers and others

Strategic Report
for the year ended 31st March 2021

Customers and suppliers are the key stakeholders in our business. In a competitive price driven environment, stock is the vital component at the keenest price. We engage in regular communication with our suppliers as well as customers. We recognise the fact that the stronger the relationships with suppliers the more we are able to serve our customers better. We remain committed to all our stakeholder for ethical business practices. The Company has put in practice a code of business conduct and ethics (CoBE) , every employee at Dr Reddy's is required to sign an undertaking, at least annually, that they have read such code and comply with its principles.

The impact of the company's operations on the community and environment

At Dr. Reddy's, Good Health Can't Wait is not just a slogan. But a belief that guides our thoughts, our behaviour and our actions. There are a number of initiatives that we've taken- from product development to patient management to helping doctors and partners delivers good health to patients.

Some of these were-life changing, for the patients. Like creating affordable option of complex, difficult to make medicines.

All of this is aimed of bringing good health to the community directly via the retail market or via being part of the supply chain to the NHS. The company is striving to ensure that the company is focused on the larger community.

The desirability of the company maintaining a reputation for high standards of business conduct

Dr. Reddys Board periodically reviews their Corporate Governance requirements as the commitment to upholding the highest standards are set at board level but is filtered down throughout the whole group organisation.

The need to act fairly as between members of the company

The Directors consider and focus its attention to ensure that the company's performance is in line with their strategic vision for both the short and long term objectives. The impact of this on all of the stakeholders is reviewed. The Directors believe they act fairly.

The Board has created a culture of honesty, integrity and respect of the Dr. Reddys core values and principles. The company that has set a number guidelines on Code of Business Conduct and Ethics (COBE) through to various Environment and Employment policies.

Principal decisions

We define principal decisions taken by the Board as those decisions in 2019/20 that are of a strategic nature and that are significant to any of our key stakeholder groups. As outlined in the FRC Guidance on the Strategic Report, we include decisions related to capital allocation and dividend policy.

REVIEW OF CLOSING POSITION

Overall, Dr Reddy's Laboratories (UK) Limited finds itself in a good financial position at the close of the 2020/21. Cash reserves of £959k were held at the year end which has decreased from £1,273 k last year. The company continues to hold sufficient cash reserves. Overall sales have increased by 5.8%, and profit before tax has decreased from 11.6% to 7.9%.

These results are reflected in a healthy balance sheet showing Net Assets of £35.1m compared to £32.9m last year.

Strategic Report
for the year ended 31st March 2021

FUTURE DEVELOPMENTS

With Covid 19 hitting the world and our industry in February/March 2020, current year also will continue to be uncertain and challenging. Dr Reddy's Laboratories UK Limited will continue to monitor situation across all areas of business identifying potential risk and plan for any mitigation. We also continue to launch new product in in 2021/22 and continue to grow our relationships.

ON BEHALF OF THE BOARD:

R Sane - Secretary

6th May 2021

Report of the Directors
for the year ended 31st March 2021

The directors present their report with the financial statements of the company for the year ended 31st March 2021.

DIVIDENDS

No dividends will be distributed for the year ended 31st March 2021.

FUTURE DEVELOPMENTS

Details of the company's future developments have been provided in the strategic report.

DIRECTORS

The directors during the year under review were:

K S Reddy
V N Mannam
S McAuliffe
P Aghanian

The beneficial interests of the directors holding office on 31st March 2021 in the issued share capital of the company were as follows:

	31.3.21	1.4.20
Ordinary £1 shares		
K S Reddy	-	-
V N Mannam	-	-
S McAuliffe	-	-
P Aghanian	-	-

FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

The company's principal financial instruments comprise bank balances, trade debtors and trade creditors. The main purpose of these instruments is to raise funds and finance the company's operations.

Revenue maintenance

The company actively markets and manages its portfolio of products to focus on revenue building and maintenance which, over the life cycle of the products can contribute to the future profits of the business.

Principle risks and uncertainties

These have been provided in the strategic report of the company.

ENGAGEMENT WITH EMPLOYEES

Dr Reddy's UK management team invites a fair and open two way relationship with all employees. All departments offer regular meetings and encourage dialogue to create an inclusive environment and develop ideas. Our employees are the heart of our business and our policy is to ensure there is no discrimination when it comes to race, age, gender or disability. All such policies are discussed at relevant HR meetings or forums and it is the management's responsibility that they are adhered to.

ENGAGEMENT WITH SUPPLIERS, CUSTOMERS AND OTHERS

Our relationships with both customers and suppliers are the key driver in our business. In a competitive price driven environment, stock is the vital component at the keenest price. This is why we need constant communication with suppliers, both third party and from our own company supply. The stronger the relationships with suppliers the more we are able to be first in class with customers on an on time in full basis. Our customer relationships both with the NHS and private wholesale and retail organisations continues to develop well and this has shown in our growth in the year.

STATEMENT OF CORPORATE GOVERNANCE ARRANGEMENTS

Dr. Reddy's Laboratories (UK) Limited believes that timely disclosures, transparent accounting policies coupled with a strong board go a long way in maintaining good corporate governance, preserving all stakeholders' trust and maximizing long-term corporate value. The company's corporate governance framework is based on the following main principles: Ethical business conduct by the board, management and employees. Well-developed systems of internal controls, Compliance to applicable local and international laws and financial reporting. Protection and facilitation of all stakeholders' rights. Adequate, timely and accurate disclosure of all material operational and financial information to relevant stakeholders.

Report of the Directors
for the year ended 31st March 2021

STREAMLINED ENERGY AND CARBON REPORTING

	2021	2020	Movement	%
	KwH	KwH	KwH	
Electricity	322,542	332,905	-10,363	-3.2
Gas	285,131	293,261	-8,130	-2.8
Total	607,673	626,166	-18,493	-3.0

The company is focused and committed to energy savings and reductions in consumption.

STATEMENT OF DIRECTORS' RESPONSIBILITIES

The directors are responsible for preparing the Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The directors are responsible for the maintenance and integrity of the corporate and financial information included on the company's website.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS

So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

AUDITORS

The auditors, cbaSadofskys, will be proposed for re-appointment at the forthcoming Annual General Meeting.

ON BEHALF OF THE BOARD:

R Sane - Secretary

6th May 2021

Report of the Independent Auditors to the Members of
Dr Reddy's Laboratories (UK) Limited

Opinion

We have audited the financial statements of Dr Reddy's Laboratories (UK) Limited (the 'company') for the year ended 31st March 2021 which comprise the Income Statement, Other Comprehensive Income, Balance Sheet, Statement of Changes in Equity and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the company's affairs as at 31st March 2021 and of its profit for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The directors are responsible for the other information. The other information comprises the information in the Strategic Report and the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements.

Report of the Independent Auditors to the Members of
Dr Reddy's Laboratories (UK) Limited

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report or the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of directors

As explained more fully in the Statement of Directors' Responsibilities, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Report of the Independent Auditors to the Members of
Dr Reddy's Laboratories (UK) Limited

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations;
- we identified the laws and regulations applicable to the company through discussions with directors and other management, and from our commercial knowledge and experience of the pharmaceutical industry;
- we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the company, including the Companies Act 2006, UK tax legislation, and data protection, anti-bribery, employment, environmental, health and safety legislation along with industry specific regulations and requirements such as compliance with regulations set out by the Department of Health and the Medicines and Healthcare products Regulatory Agency (MHRA);
- we assessed the extent of compliance with the laws and regulations identified above through making enquiries of management and inspecting legal correspondence; and
- identified laws and regulations were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit.

We assessed the susceptibility of the company's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

- making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud; and
- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

To address the risk of fraud through management bias and override of controls, we:

- performed analytical procedures to identify any unusual or unexpected relationships;
- tested journal entries to identify unusual transactions;
- assessed whether judgements and assumptions made in determining the accounting estimates set out in note 2 were indicative of potential bias; and
- investigated the rationale behind significant or unusual transactions.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- agreeing financial statement disclosures to underlying supporting documentation;
- reading the minutes of meetings of those charged with governance;
- enquiring of management as to actual and potential litigation and claims; and
- reviewing correspondence with HMRC, relevant regulators, and the company's legal advisors.

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

Report of the Independent Auditors to the Members of
Dr Reddy's Laboratories (UK) Limited

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Alan Brocklehurst (Senior Statutory Auditor)
for and on behalf of cbaSadofskys
Statutory Auditors
Princes House
Wright Street
Hull
East Yorkshire
HU2 8HX

6th May 2021

Income Statement
for the year ended 31st March 2021

	Notes	2021 £	£	2020 £	£
TURNOVER	3		38,892,768		36,748,791
Cost of sales			28,890,031		27,119,580
GROSS PROFIT			10,002,737		9,629,211
Distribution costs		701,475		606,358	
Administrative expenses		6,658,865		5,122,406	
			7,360,340		5,728,764
OPERATING PROFIT	5		2,642,397		3,900,447
Interest receivable and similar income			418,090		360,325
PROFIT BEFORE TAXATION			3,060,487		4,260,772
Tax on profit	6		770,644		791,299
PROFIT FOR THE FINANCIAL YEAR			2,289,843		3,469,473

The notes form part of these financial statements

Other Comprehensive Income
for the year ended 31st March 2021

	Notes	2021 £	2020 £
PROFIT FOR THE YEAR		2,289,843	3,469,473
OTHER COMPREHENSIVE INCOME		—	—
TOTAL COMPREHENSIVE INCOME		—	—
FOR THE YEAR		<u>2,289,843</u>	<u>3,469,473</u>

Balance Sheet
31st March 2021

	Notes	2021 £	£	2020 £	£
FIXED ASSETS					
Intangible assets	7		842,054		1,104,101
Tangible assets	8		<u>1,555,111</u>		<u>2,827,590</u>
			2,397,165		3,931,691
CURRENT ASSETS					
Stocks	9	7,681,642		5,525,772	
Debtors	10	40,469,779		34,950,516	
Cash at bank and in hand		<u>958,595</u>		<u>1,273,237</u>	
		49,110,016		41,749,525	
CREDITORS					
Amounts falling due within one year	11	<u>16,350,160</u>		<u>12,792,415</u>	
NET CURRENT ASSETS			32,759,856		28,957,110
TOTAL ASSETS LESS CURRENT LIABILITIES			35,157,021		32,888,801
PROVISIONS FOR LIABILITIES	12		<u>11,311</u>		<u>32,934</u>
NET ASSETS			35,145,710		32,855,867
CAPITAL AND RESERVES					
Called up share capital	13		1,000		1,000
Other reserves	14		879,601		879,601
Retained earnings	14		<u>34,265,109</u>		<u>31,975,266</u>
SHAREHOLDERS' FUNDS			35,145,710		32,855,867

The financial statements were approved by the Board of Directors and authorised for issue on 6th May 2021 and were signed on its behalf by:

S McAuliffe - Director

Statement of Changes in Equity
for the year ended 31st March 2021

	Called up share capital £	Retained earnings £	Other reserves £	Total equity £
Balance at 1st April 2019	1,000	28,505,793	879,601	29,386,394
Changes in equity				
Total comprehensive income	-	3,469,473	-	3,469,473
Balance at 31st March 2020	1,000	31,975,266	879,601	32,855,867
Changes in equity				
Total comprehensive income	-	2,289,843	-	2,289,843
Balance at 31st March 2021	1,000	34,265,109	879,601	35,145,710

The notes form part of these financial statements

Notes to the Financial Statements
for the year ended 31st March 2021

1. STATUTORY INFORMATION

Dr Reddy's Laboratories (UK) Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Financial Reporting Standard 102 - reduced disclosure exemptions

The company has taken advantage of the following disclosure exemptions in preparing these financial statements, as permitted by FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland":

- the requirements of Section 7 Statement of Cash Flows;
- the requirement of paragraph 33.7.

Turnover

Turnover represents invoiced sales of goods, excluding value added tax, less discounts and rebates.

Intangible assets

Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents and licences are being amortised evenly over their estimated useful life of five years.

Intangible assets

Products using patents are capitalised at the date of the patent. The residual value of these patents are being amortised evenly over their estimated useful lives.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Freehold property	- Straight line at 1%
Improvements to property	- Over the period of the lease
Plant and machinery	- 10% to 20% on cost and 20% on reducing balance
Fixtures and fittings	- Straight line over 3 years

Stocks

Raw materials, packing materials and work in progress are valued at cost. Finished goods are valued at the lower of cost and net realisable value. Stock is valued after making due allowance for obsolete and slow moving stock.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Notes to the Financial Statements - continued
for the year ended 31st March 2021

2. ACCOUNTING POLICIES - continued

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research, regulatory and development cost

Expenditure on research, regulatory and development cost is written off in the year in which it is incurred.

Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits

The company makes contributions to the private pension funds of directors and staff. Contributions payable for the year are charged in the profit and loss account.

Stock based compensation

The stock options taken up in the ultimate parent company, Dr Reddy's Laboratories Limited, by staff members of subsidiary companies are accounted for in the accounts of the subsidiary company.

Regulatory and trade licence fees

Expenditure in respect of the renewal of trade licences has been charged to the profit and loss account when it has been incurred.

Going concern

The company has the long term support from the group and as a consequence, the directors believe that the company is well placed to manage its business risks successfully despite the uncertain economic outlook.

The directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis in preparing the annual financial statements.

Further information regarding the company's business activities, together with the factors likely to affect its future development, performance and position is set out in the Strategic Report.

Notes to the Financial Statements - continued
for the year ended 31st March 2021

3. TURNOVER

The turnover and profit before taxation are attributable to the principal activities of the company.

An analysis of turnover by geographical market is given below:

	2021 £	2020 £
United Kingdom	33,937,033	30,054,423
Europe and other countries	4,955,735	6,694,368
	<u>38,892,768</u>	<u>36,748,791</u>

4. EMPLOYEES AND DIRECTORS

	2021 £	2020 £
Wages and salaries	3,456,971	3,226,248
Social security costs	294,454	279,239
Other pension costs	219,797	183,115
	<u>3,971,222</u>	<u>3,688,602</u>

The average number of employees during the year was as follows:

	2021	2020
Directors and administration	48	54
Production	20	22
	<u>68</u>	<u>76</u>

	2021 £	2020 £
Directors' remuneration	<u>139,531</u>	<u>192,365</u>

The number of directors to whom retirement benefits were accruing was as follows:

Money purchase schemes	<u>1</u>	<u>1</u>
------------------------	----------	----------

5. OPERATING PROFIT

The operating profit is stated after charging/(crediting):

	2021 £	2020 £
Hire of plant and machinery	10,891	9,369
Depreciation - owned assets	131,314	180,063
Loss/(profit) on disposal of fixed assets	92,202	(4,000)
Patents and licences amortisation	277,031	198,087
Auditors' remuneration	6,400	6,400
Auditors' remuneration for non audit work	2,750	2,750
Foreign exchange differences	<u>267,918</u>	<u>(301,209)</u>

Notes to the Financial Statements - continued
for the year ended 31st March 2021

6. TAXATION

Analysis of the tax charge

The tax charge on the profit for the year was as follows:

	2021	2020
	£	£
Current tax:		
UK corporation tax	792,267	758,365
Deferred taxation	(21,623)	32,934
Tax on profit	<u>770,644</u>	<u>791,299</u>

UK corporation tax has been charged at 19% .

Reconciliation of total tax charge included in profit and loss

The tax assessed for the year is higher than the standard rate of corporation tax in the UK. The difference is explained below:

	2021	2020
	£	£
Profit before tax	<u>3,060,487</u>	<u>4,260,772</u>
Profit multiplied by the standard rate of corporation tax in the UK of 19% (2020 - 19%)	581,493	809,547
Effects of:		
Depreciation on non-qualifying assets	5,443	7,655
Stock-based compensation	4,607	(202)
Deferred tax asset not provided last year	-	(25,701)
Impairment of non-qualifying assets	179,101	-
Total tax charge	<u>770,644</u>	<u>791,299</u>

Notes to the Financial Statements - continued
for the year ended 31st March 2021

7. INTANGIBLE FIXED ASSETS

	Patents and licences £
COST	
At 1st April 2020	1,781,474
Additions	192,186
Disposals	(295,467)
At 31st March 2021	<u>1,678,193</u>
AMORTISATION	
At 1st April 2020	677,373
Amortisation for year	277,031
Eliminated on disposal	(118,265)
At 31st March 2021	<u>836,139</u>
NET BOOK VALUE	
At 31st March 2021	<u>842,054</u>
At 31st March 2020	<u>1,104,101</u>

8. TANGIBLE FIXED ASSETS

	Freehold property £	Improvements to property £	Plant and machinery £	Fixtures and fittings £	Totals £
COST					
At 1st April 2020	2,636,044	34,991	3,924,562	780,709	7,376,306
Additions	-	-	-	4,405	4,405
Disposals	-	-	(425,733)	-	(425,733)
Impairments	(1,365,649)	-	(3,210,599)	(553,067)	(5,129,315)
At 31st March 2021	<u>1,270,395</u>	<u>34,991</u>	<u>288,230</u>	<u>232,047</u>	<u>1,825,663</u>
DEPRECIATION					
At 1st April 2020	387,433	34,630	3,422,341	704,312	4,548,716
Charge for year	35,578	-	64,176	31,560	131,314
Eliminated on disposal	-	-	(425,733)	-	(425,733)
Impairments	(423,011)	-	(3,024,880)	(535,854)	(3,983,745)
At 31st March 2021	<u>-</u>	<u>34,630</u>	<u>35,904</u>	<u>200,018</u>	<u>270,552</u>
NET BOOK VALUE					
At 31st March 2021	<u>1,270,395</u>	<u>361</u>	<u>252,326</u>	<u>32,029</u>	<u>1,555,111</u>
At 31st March 2020	<u>2,248,611</u>	<u>361</u>	<u>502,221</u>	<u>76,397</u>	<u>2,827,590</u>

Net book value at 31st March 2021 includes Assets held for resale of £1.5m.

Notes to the Financial Statements - continued
for the year ended 31st March 2021

9. STOCKS

	2021	2020
	£	£
Packaging materials	4,865	196,966
Work-in-progress	21,696	238,135
Finished goods	7,655,081	5,090,671
	<u>7,681,642</u>	<u>5,525,772</u>

10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2021	2020
	£	£
Trade debtors	10,307,623	11,025,621
Amounts due from fellow subsidiaries	29,992,187	23,811,092
Amount due from ultimate parent company	13,275	-
Prepayments and accrued income	156,694	113,803
	<u>40,469,779</u>	<u>34,950,516</u>

11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2021	2020
	£	£
Trade creditors	2,005,861	1,760,305
Amount due to ultimate parent company	11,149,708	7,319,655
Amounts owed to fellow subsidiaries	744,468	311,878
Taxation	354,671	325,439
Social security and other taxes	181,685	486,106
Other creditors	286,509	27,408
Accrued expenses	1,593,869	2,546,407
Deferred income	33,389	15,217
	<u>16,350,160</u>	<u>12,792,415</u>

12. PROVISIONS FOR LIABILITIES

	2021	2020
	£	£
Deferred tax		
Accelerated capital allowances	<u>11,311</u>	<u>32,934</u>

	Deferred tax
	£
Balance at 1st April 2020	32,934
Credit to Income Statement during year	(21,623)
Balance at 31st March 2021	<u>11,311</u>

Notes to the Financial Statements - continued
for the year ended 31st March 2021

13. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:	Class:	Nominal value:	2021 £	2020 £
1,000	Ordinary	£1	<u>1,000</u>	<u>1,000</u>

14. RESERVES

	Retained earnings £	Other reserves £	Totals £
At 1st April 2020	31,975,266	879,601	32,854,867
Profit for the year	2,289,843		2,289,843
At 31st March 2021	<u>34,265,109</u>	<u>879,601</u>	<u>35,144,710</u>

15. ULTIMATE PARENT COMPANY

The company's immediate parent company is Dr Reddy's Laboratories (EU) Limited, a company registered in England and Wales. The group financial statements are available to the public and may be obtained from Steanard Lane, Mirfield, West Yorkshire, WF14 8HZ.

The company's ultimate parent and controlling company is Dr Reddy's Laboratories Limited, a company incorporated in India. The group financial statements are available to the public and may be obtained from Door No 8-2-337, Road No 3, Banjara Hills, Hyderabad - 500034, India.

Notes to the Financial Statements - continued
for the year ended 31st March 2021

16. RELATED PARTY DISCLOSURES

At the balance sheet date, the company owed the amounts to related parties:

	2021	2020
£		
Dr Reddy's Laboratories Limited	11,149,708	7,319,655
Dr Reddy's S.A	-	200,552
Dr Reddy's Laboratories S.R.L	131,548	14,609
Reddy Pharma SAS	459,849	49,778
Dr Reddy's Laboratories (EU) Limited	153,535	-

At the balance sheet date, the company was owed amounts from the following related parties:

	2021	2020
£		
Dr Reddy's Laboratories S.R.L	(84,617)	(162,670)
Betapharm Arzneimittel GmbH	67,115	15,934
Dr Reddy's Pharma Iberia	33,191	421,265
Dr Reddy's S.A	29,945,922	23,536,563
Dr Reddy's Laboratories (EU) Limited	31,800	-
Dr Reddy's Laboratories Limited	13,275	-

During the year the company made purchases on normal commercial terms to the following related parties:

	2021	2020
£		
Dr Reddy's Laboratories Limited	17,516,550	15,477,868
Industrias Quimicas Falcon	63,520	140,924
Dr Reddy's S.A	213,529	200,552
Reddy Pharma SAS	461,476	-

During the year the company made QC sales on normal commercial terms to the following related parties:

	2021	2020
£		
Betapharm Arzneimittel GmbH	-	15,934

During the year the company made sales on normal commercial terms to the following related parties:

	2021	2020
£		
Dr Reddy's Pharma Iberia	105,400	(4,264)
Betapharm Arzneimittel GmbH	607,382	71,803
Dr Reddy's Laboratories S.R.L	(93,477)	(167,828)
Reddy Pharma SAS	-	290,260

During the year the company received salary recharges from the following related parties:

	2021	2020
£		
Dr Reddys' Laboratories (EU) Limited	314,340	150,474

During the year the company had given a loan to the following related parties:

	2021	2020
£		
Dr Reddy's S.A	6,400,000	7,900,000

During the year the company had charged interest on the loans to the following related parties:

	2021	2020
£		

Notes to the Financial Statements - continued
for the year ended 31st March 2021

Dr Reddy's S.A

415,950

353,429

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.